Chair of the Board of Directors, Novo Nordisk
Verified interview transcripts, podcast appearances, and direct quotes from Lars Sorensen, Chair of the Board of Directors at Novo Nordisk. AI-verified speaker identity with full-text searchable transcripts.
“I do believe that it's upon the Western economies in the United States and in Europe and also in Japan, the wealthy nations, to pay for the innovation such that other countries, emerging markets and lower income countries, can benefit from this when the drugs become off patent and can be made available.”
“The price of developing a new drug today is more than a billion dollars, and it's an effort which requires skills from all the way from biology to toxicology to animal testing to human testing to administration. So it's a very complex process, and so far we've not seen that many companies in the emerging markets being...”
“We hope that Bydureon by now being more competitive by having a longer acting product than than Victoza will assist us in creating an interest in the GLP-1 segment because we're the market leaders at the moment and so we believe that they will expand the interest in the GLP-1 segment, expand the market, they will gain...”
“There are a number of uncertainties when we look at the world economy, of course there are concerns about especially the European economies that we could see further headwind in terms of healthcare reforms, also in terms of uncertainty on the demands for our product that also then leads to more competitive scenarios. S...”
Novo Nordisk, Danish Manufacturer of Insulin in collaboration with Kenya Government to drop cost of insulin through Bottom of The Pyramid project. The BoP project currently being implemented in Nyeri and Dagoretti will reduce the cost of insulin to 500 Kshs from 1,800 K.shs at 27 Faith Based Health Facilities in Nyeri and Dagoretti.
SEE MORE ON CANAL INTERNACIONAL: www.ci-webtv.com Nordisk CEO Lars Rebien Sørensen, on 2011 Financial Results Nordisk CEO and president Lars Rebien Sørensen on sales growth in 2011 by 11%, measured in local currencies, Victoza and the competition by Amylins's once-weekly GLP-1 product, Bydureon, launced in Europe and just approved in the US, regulatory update on Degludec, the ultra-long acting insulin from Novo Nordisk now submitted for approval in the US, Europe and Japan, on the Novo Nordisk pipeline, expectations of sales growth in 2012 between 7 and 11 % and finally the fact that Lars Re…
Sign in to search the full transcript archive, filter by topic, and access every quote from Lars Sorensen.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →